Bioglutide™ & Medicare: A Strategy for Affordable Metabolic Care

Updated: August 17, 2025 • Educational content only.

Biomed is proactively discussing with CMS to position Bioglutide™ (NA‑931) not only as an effective metabolic therapy—but also as an accessible and affordable one. Here’s how they’re addressing the US payor landscape.

Why Cost Matters

• Many patients discontinue injectables like semaglutide due to high cost—over $1,000/month. 
• With Medicare negotiation power, Bioglutide could be positioned as a cost-effective oral therapy.

Biomed’s Strategic Plan

• Present Phase 2 data showing strong efficacy and tolerability. 
• Engage with CMS and private insurers to align pricing and reimbursement frameworks.
• Position Bioglutide as both clinically effective and convenient with oral dosing.

Why This Matters

Aligning Bioglutide with affordability goals could improve adherence and long-term access, especially among Medicare beneficiaries.

FAQs

Will Bioglutide be cheaper than existing injectables?
Pricing hasn't been finalized, but oral dosing and potential insurance coverage may reduce out-of-pocket costs.

Disclaimer

 This content is intended for informational and educational purposes only and is not intended to promote or sell any product. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves.